Disorders of gastrointestinal motility associated with diabetes mellitus.
Gastrointestinal symptoms such as vomiting, constipation, diarrhea, and fecal incontinence occur frequently in patients with diabetes mellitus. In a survey of 136 diabetic outpatients, 76% had one or more gastrointestinal symptoms, the commonest symptom being constipation (found in 60%). In many cases these symptoms are thought to be due to abnormal gastrointestinal motility that, in turn, may be a manifestation of diabetic autonomic neuropathy involving the gastrointestinal tract. The pathophysiology of these gastrointestinal symptoms, clarified in recent studies, and the clinical features and treatment of these problems in diabetic patients are reviewed.
D001342:Autonomic Nervous System Diseases / Q000150:complications; D001626:Bethanechol Compounds / Q000494:pharmacology; D003248:Constipation / Q000188:drug therapy / Q000503:physiopathology; D048909:Diabetes Complications; D016883:Diabetic Ketoacidosis / Q000150:complications; D003929:Diabetic Neuropathies / Q000150:complications; D003967:Diarrhea / Q000188:drug therapy / Q000503:physiopathology; D004594:Electrophysiology; D005242:Fecal Incontinence / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D005746:Gastric Emptying; D005767:Gastrointestinal Diseases / Q000150:complications*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008564:Membrane Potentials; D008787:Metoclopramide / Q000627:therapeutic use; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D010146:Pain / Q000209:etiology; D010640:Phenothiazines / Q000627:therapeutic use; D013270:Stomach / Q000503:physiopathology; D014839:Vomiting / Q000188:drug therapy / Q000209:etiology
D001626:Bethanechol Compounds; D010640:Phenothiazines; D008787:Metoclopramide